| Prev Close | 59.88 |
| Day Low/High | 58.81 / 59.95 |
| 52 Wk Low/High | 42.88 / 64.60 |
| Avg Volume | 7.06M |
| Exchange | NYSE |
| Shares Outstanding | 1.75B |
| Market Cap | 104.57B |
| EPS | 0.30 |
| P/E Ratio | 285.14 |
| Div & Yield | 1.12 (1.81%) |
Stocks finish mixed on Wednesday amid a sharp decline in IBM shares.
Jim Cramer and our other experts look at banks, three sections to trade, and REITs.
FreeStyle Libre already has over 50,000 users in the U.S. since being approved for sale in the U.S. last September.
Jim discusses latest results for Abbott Labs, Goldman Sachs and more.
Overall, it was a very solid quarter by Abbott.
Abbott sees full year earnings of between $2.80 to $2.90 a share after a solid first quarter that topped Wall Street forecasts.
Market reactions have ranged anywhere from lackluster to outright negative. What gives?
U.S. stock futures rise modestly; IBM tumbles after it reports a weaker-than-expected profit margin; the NTSB says the blown engine on a Southwest plane had 'metal fatigue.'
Abbott's Freestyle Libre in September secured FDA approval and in January, the company said the device had received reimbursement from the Centers for Medicare & Medicaid Services.
Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.
Not every battle is worth fighting, says Jim Cramer. That's especially true if you own shares of Newell Brands.
Curtis Morgan, president and CEO of Vistra Energy, talks to Jim Cramer about the outlook for coal and renewables.
Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.
Latest results due from UnitedHealth, Goldman Sachs, Abbott and more.
Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!
The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
We have long been fans of UNH as the company is a strong defensive name.
- THE CARDIOMEMS™ HF SYSTEM IS THE FIRST AND ONLY FDA-APPROVED HEART FAILURE MONITOR PROVEN TO SIGNIFICANTLY REDUCE HEART FAILURE HOSPITAL ADMISSIONS AND IMPROVE QUALITY OF LIFE
Fears of a trade war and a Fed rate hike marked a volatile week.
Here's what you need to know now for Thursday, March 22.
- National reimbursement adds the device into Japan's health insurance system, which enables greater access for patients
Sectors are saying different things about rates, but new Fed chief Jerome Powell could provide clarity at his first press conference on Wednesday.
White House gets new economic adviser.
Jim Cramer focuses on Merck, Eli Lilly, Abbott Labs, Phillips 66, Five Below, and Cintas in the Lightning Round.
Do we trade on the news out of Washington? Jim Cramer talks about Larry Kudlow and his stand on economic growth.
Jim Cramer highlights Corning, Freeport-McMoran, McDonald's, Ventas, Kindred Healthcare.
